Writing to you specifically because our family is (trying to) think about my father's case not just as a disease to...

Your Father's Case: Strategic Planning for Esophageal Cancer

Thank you for sharing this detailed clinical picture and for thinking strategically about your father's care. You're right to be planning several moves ahead—this approach aligns with how leading oncologists now think about advanced cancers. Let me address your concerns directly.

---

UNDERSTANDING HIS CLINICAL SITUATION

What his staging tells us: Your father has locally advanced esophageal cancer (TxN1M0) with nodal involvement but no distant metastases—this is a critical distinction. The fact that PET/CT confirmed M0 (no spread) is genuinely good news and explains why aggressive multimodal therapy (chemotherapy + immunotherapy + surgery) is the standard approach.

His biomarker profile is strategically important:

• HER2 negative — rules out HER2-targeted therapies (trastuzumab), but opens other pathways
• PDL1 CPS 8 — this is a moderate PD-L1 expression level. According to NCCN Guidelines for esophageal cancer, this makes him a reasonable candidate for checkpoint inhibitor therapy, which is why durvalumab (an anti-PD-L1 drug) is part of his regimen
• MSS (microsatellite stable) — rules out mismatch repair deficiency, so he's not a candidate for checkpoint inhibitor monotherapy alone (which is why combination therapy with chemotherapy is appropriate)
• Claudin 18.2 and FGFR2b testing pending — these are critical biomarkers. Claudin 18.2 positivity opens the door to zolbetuximab (a monoclonal antibody), which has shown survival benefit in gastric/GEJ cancers. FGFR2b alterations could indicate eligibility for FGFR inhibitors. These results will likely inform your post-surgery strategy.

---

YOUR TREATMENT PLAN: WHAT THE EVIDENCE SHOWS

The D-FLOT + durvalumab approach your father is receiving is evidence-based and appropriate:

According to NCCN Guidelines for Esophageal Cancer, the combination of:

• FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, docetaxel) — the standard neoadjuvant regimen
• Durvalumab (anti-PD-L1 checkpoint inhibitor) — added based on emerging data showing improved outcomes when combined with chemotherapy

...followed by robotic esophagectomy and durvalumab maintenance represents state-of-the-art care for locally advanced disease.

---

YOUR MOST PRESSING CONCERN: POSITIVE ctDNA POST-SURGERY

You've identified the real frontier question: What happens if Signatera shows detectable circulating tumor DNA (ctDNA) after surgery, despite negative imaging?

You're correct that this is an evolving area without a fully established protocol. Here's what the current evidence shows:

The Clinical Reasoning (How Oncologists Think About This):

According to discussions in the CancerPatientLab webinars on minimal residual disease (MRD), this exact scenario represents a significant gap in current oncology practice:

"Patients who still have circulating tumor DNA in their blood face a very high risk of recurrence. The challenge is, we're spending billions on this testing particularly in the US but there's currently no actionable path forward."

What ctDNA positivity likely means:

• Detectable ctDNA after surgery suggests residual disease at the molecular level—cancer cells or fragments circulating in the blood that imaging cannot yet detect
• This is associated with higher recurrence risk, but detection alone doesn't automatically mean immediate treatment changes
• The key question becomes: How aggressive should the response be?

General Approaches That Exist (What Options Are Being Considered):

Based on emerging evidence and expert practice, oncologists are considering several strategies when faced with positive post-surgery ctDNA:

1. Intensified Surveillance

• Increase imaging frequency (CT/PET scans more often than standard intervals)
• More frequent ctDNA monitoring (potentially monthly rather than quarterly)
• Earlier detection of radiographic recurrence if it occurs
• Rationale: If recurrence is coming, catching it earlier may allow intervention before it becomes widespread

2. Extended or Intensified Systemic Therapy

• Continuation of durvalumab beyond standard maintenance duration
• Addition of targeted therapy if Claudin 18.2 or FGFR2b testing shows actionable mutations
• Consideration of chemotherapy rechallenge or different chemotherapy regimens
• Rationale: Positive ctDNA suggests chemotherapy-resistant disease; different agents or combinations might work

3. Biomarker-Driven Precision Approaches

• If Claudin 18.2 positive: Zolbetuximab (Aivita) combined with chemotherapy has shown survival benefit in gastric/GEJ cancers and is being studied in esophageal cancer
• If FGFR2b altered: FGFR inhibitors (e.g., infigratinib, futibatinib) could be considered
• Repeat tissue biopsy if feasible, to understand what's changed in the tumor biology
• Rationale: The tumor may have evolved; new biomarkers may reveal new vulnerabilities

4. Clinical Trial Enrollment

• Trials specifically designed for MRD/ctDNA-positive patients are emerging
• Some trials test whether early intervention based on ctDNA improves outcomes
• Rationale: This is an active research area; trials may offer access to novel combinations

5. Monitoring Without Immediate Escalation

• Some oncologists advocate for close monitoring with treatment escalation only if imaging shows recurrence
• Rationale: Lead time bias—detecting ctDNA earlier doesn't always improve outcomes if you can't treat it effectively anyway
• Caveat: This is more conservative and depends on your father's overall health and preferences

---

STRATEGIC QUESTIONS TO ASK YOUR MEDICAL ONCOLOGIST (May 15th appointment)

These questions will help you and your father develop a concrete plan before you get Signatera results:

On ctDNA Surveillance:

1. "If my post-surgery Signatera shows positive ctDNA while imaging is negative, what would be your recommended next step? Do you have a protocol or decision tree for this scenario?"
2. "How would you distinguish between ctDNA that requires immediate treatment escalation versus ctDNA that warrants intensified monitoring?"
3. "What imaging would you order, and how frequently, if Signatera becomes positive?"

On Biomarker-Driven Decisions: 4. "Once we have Claudin 18.2 and FGFR2b results, how would those results change our post-surgery strategy if ctDNA is positive?" 5. "Are there clinical trials specifically for esophageal cancer patients with positive ctDNA that my father might be eligible for?"

On Treatment Sequencing: 6. "How long would you plan to continue durvalumab maintenance, and would that change if ctDNA becomes positive?" 7. "If we need to escalate therapy based on ctDNA, what would be your preferred next regimen—and would you consider combination approaches (e.g., checkpoint inhibitor + targeted therapy + chemotherapy)?"

On Surveillance Strategy: 8. "What's your approach to ctDNA monitoring frequency? Would you increase it if the first post-surgery test is positive?" 9. "Are there other biomarkers beyond ctDNA (like fragmentomics or other liquid biopsy markers) you'd consider to refine the recurrence risk?"

---

WHAT THE EVIDENCE SAYS ABOUT PLANNING AHEAD

The CancerPatientLab webinars emphasize several strategic principles that apply directly to your situation:

From the multi-omic analysis framework:

• Integrate data from multiple sources — ctDNA + imaging + biomarkers + clinical context
• Identify specific vulnerabilities — your pending Claudin 18.2 and FGFR2b results will do this
• Plan ahead and keep treatments in reserve — don't use all your options at once; sequence them strategically
• Validate findings — if ctDNA is positive, consider confirming with repeat testing or tissue biopsy before major treatment changes
• Keep disease burden as low as possible — this supports aggressive early intervention if ctDNA becomes positive

**